Fresenius completes sale of non-core businesses
This article was originally published in Clinica
Fresenius Medical Care (FMC) has sold its remaining non-core business, the US homecare division, to the private company, Home Medical of America. Last November, FMC announced its intention to sell the business, along with its US diagnostic business, which it sold last month to Navix Radiology Systems (see Clinica No 817, p 11). The proceeds from the two divestments are estimated at $100 million.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.